Accelerate Next Generation TCR Engineering, Enhance Target Identification, & Improve Solid Tumor Persistence to Transform
Clinical & Scalable Development for Patients in Need

April 23-25, 2024 | Boston MA

Join the 5th TCR-based Therapies for Solid Tumors Summit

Our core commitment centres on advancing R&D and Clinical Development strategies for TCR therapies, aiming to harness their immense potential in targeting solid tumors. These therapies offer promising avenues for enhancing treatment methodologies, thereby fostering optimism for improved outcomes among patients grappling with these challenging conditions.

The recent submission of a Biologics License Application (BLA) by Adaptimmune is a remarkable milestone, signifying remarkable progress in gaining regulatory approval for their TCR-based cancer therapy. This achievement indicates a pivotal step forward, paving the way for broader accessibility of this innovative treatment to patients in critical need.

The 5th TCR-based Therapies for Solid Tumors Summit returns as your only TCR conference where TCR pipelines have the centre stage, serving as your ultimate platform to network with the most senior industry leaders in biopharma dedicated to accelerating clinical and commercial development of TCR-based therapeutics.

The World-Class Speaker Faculty Includes:

What Your Peers Have to Say:

''The 5th TCR-based Therapies for Solid Tumors Summit is the premiere event for researchers investigating TCR-based therapies. I look forward to great presentations and stimulating discussions with my colleagues'' – Regeneron Pharmaceuticals - 2024 Speaker